EPZM
Price:
$1.47
Market Cap:
$0
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor...[Read more]
Industry
Biotechnology
IPO Date
2013-05-31
Stock Exchange
NASDAQ
Ticker
EPZM
According to Epizyme, Inc.’s latest financial reports and current stock price. The company's current ROE is -305.86%. This represents a change of 156.71% compared to the average of -119.15% of the last 4 quarters.
The mean historical ROE of Epizyme, Inc. over the last ten years is 75.80%. The current -305.86% ROE has changed -503.51% with respect to the historical average. Over the past ten years (40 quarters), EPZM's ROE was at its highest in in the December 2021 quarter at 244.83%. The ROE was at its lowest in in the March 2022 quarter at -499.10%.
Average
75.80%
Median
-52.24%
Minimum
-125.31%
Maximum
1.21%
Discovering the peaks and valleys of Epizyme, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 927.79%
Maximum Annual ROE = 1.21%
Minimum Annual Increase = -1068.68%
Minimum Annual ROE = -125.31%
| Year | ROE | Change |
|---|---|---|
| 2021 | 1.21% | -1068.68% |
| 2020 | -125.31% | 143.66% |
| 2019 | -51.43% | -3.07% |
| 2018 | -53.06% | -7.02% |
| 2017 | -57.06% | 4.43% |
| 2016 | -54.64% | -30.02% |
| 2015 | -78.08% | 127.53% |
| 2014 | -34.32% | 927.79% |
| 2013 | -3.34% | -343.18% |
| 2012 | 1.37% | -96.68% |
The current ROE of Epizyme, Inc. (EPZM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
345.71%
5-year avg
185.40%
10-year avg
75.80%
Epizyme, Inc.’s ROE is greater than Acelyrin, Inc. (-54.74%), greater than CARGO Therapeutics, Inc. Common Stock (-69.24%), greater than Third Harmonic Bio, Inc. (-19.27%), greater than Inozyme Pharma, Inc. (-159.97%), less than Celularity Inc. (763.31%), greater than Catabasis Pharmaceuticals, Inc. (-24.29%), greater than Spectrum Pharmaceuticals, Inc. (-207.06%), less than 2seventy bio, Inc. (-1.84%), greater than Alaunos Therapeutics, Inc. (-167.97%), greater than Inhibrx Biosciences, Inc. (-186.06%),
| Company | ROE | Market cap |
|---|---|---|
| -54.74% | $229.17M | |
| -69.24% | $216.19M | |
| -19.27% | $242.79M | |
| -159.97% | $258.25M | |
| 763.31% | $31.27M | |
| -24.29% | $234.86M | |
| -207.06% | $210.38M | |
| -1.84% | $266.14M | |
| -167.97% | $8.93M | |
| -186.06% | $225.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Epizyme, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Epizyme, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Epizyme, Inc.'s ROE?
How is the ROE calculated for Epizyme, Inc. (EPZM)?
What is the highest ROE for Epizyme, Inc. (EPZM)?
What is the 3-year average ROE for Epizyme, Inc. (EPZM)?
What is the 5-year average ROE for Epizyme, Inc. (EPZM)?
How does the current ROE for Epizyme, Inc. (EPZM) compare to its historical average?